The Experts below are selected from a list of 7470 Experts worldwide ranked by ideXlab platform
Nancy J Halnon - One of the best experts on this subject based on the ideXlab platform.
-
understanding the correlation between dsa complement activation and antibody mediated rejection in heart transplant recipients
Transplantation, 2018Co-Authors: Qiuheng Zhang, Michelle J Hickey, Diana Drogaliskim, Ying Zheng, David W Gjertson, Martin Cadeiras, T Khuu, A Baas, E C Depasquale, Nancy J HalnonAbstract:BACKGROUND Donor-specific HLA antibodies (DSA) are associated with increased rates of rejection and of graft failure in cardiac transplantation. The goal of this study was to determine the association of preformed and posttransplant development of newly detected DSA (ndDSA) with antibody-mediated rejection (AMR) and characterize the clinical relevance of complement-activating DSA in heart allograft recipients. METHODS The study included 128 adult and 48 pediatric heart transplant patients transplanted between 2010 and 2013. Routine posttransplant HLA antibody Testing was performed by IgG single-antigen Bead Test. The C3d single-antigen Bead assay was used to identify complement-activating antibodies. Rejection was diagnosed using International Society for Heart and Lung Transplantation criteria. RESULTS In this study, 22 patients were transplanted with preexisting DSA, and 43 patients developed ndDSA posttransplant. Pretransplant (P < 0.05) and posttransplant (P < 0.001) ndDSA were associated with higher incidence of AMR. Patients with C3d + DSA had significantly higher incidence of AMR compared with patients with no DSA (P < 0.001) or patients with C3d-DSA (P = 0.02). Nine (36%) of 25 patients with AMR developed transplant coronary artery disease compared with 17 (15.9%) of 107 patients without AMR (P < 0.05). Among the 47 patients who received ventricular assistant device (VAD), 7 of 9 VAD+ patients with preformed DSA experienced AMR compared with 7 of 38 VAD+ patients without preformed DSA, indicating presensitization to donor HLA significantly increased the risk of AMR (P < 0.01). CONCLUSIONS Preformed and posttransplant ndDSA were associated with AMR. C3d + DSA correlates with complement deposition on the graft and higher risk of AMR which may permit the application of personalized immunotherapy targeting the complement pathway.
Lars Mattsson - One of the best experts on this subject based on the ideXlab platform.
-
Improved glass bonding with plasma treatment
Applied Adhesion Science, 2018Co-Authors: Åsa Lundevall, Peter Sundberg, Lars MattssonAbstract:Bonding of automotive glass is generally performed with 1C PUR adhesive on a primed ceramic frit or naked glass surface. The aim of this research was to replace the chemistry of the primer with an atmospheric pressure plasma treatment (APPT) with compressed air for cleaning and activation directly before bonding. Characterization of the glass surface was performed with surface energy through contact angle, XPS, TOF-SIMS and adhesive peel Bead Test. The results show that APPT treatment can clean the surface, improve the wetting, improve the bonding but reduce the number of non bridging oxygen for the adhesive to bond to. The highest measured spot temperature of the glass during APPT was measured up to 270 °C, but the temperature was depending on process parameters. A reduction in non bridging oxygen was also seen during heating of the reference glass at 100 °C. A further reaction was seen when measured after a 550 °C heating. A modified APPT treatment with deionized water as precursor was used. The results show that the APPT with water does not lower the level of non bridging oxygen and the bonding was further improved.
Mattsso Lars - One of the best experts on this subject based on the ideXlab platform.
-
Improved glass bonding with plasma treatment
'Springer Science and Business Media LLC', 2018Co-Authors: Lundevall Åsa, Sundberg Pete, Mattsso LarsAbstract:Bonding of automotive glass is generally performed with 1C PUR adhesive on a primedceramic frit or naked glass surface. The aim of this research was to replace the chemistryof the primer with an atmospheric pressure plasma treatment (APPT) with compressedair for cleaning and activation directly before bonding. Characterization of theglass surface was performed with surface energy through contact angle, XPS, TOF-SIMSand adhesive peel Bead Test. The results show that APPT treatment can clean the surface,improve the wetting, improve the bonding but reduce the number of non bridgingoxygen for the adhesive to bond to. The highest measured spot temperature of theglass during APPT was measured up to 270 °C, but the temperature was depending onprocess parameters. A reduction in non bridging oxygen was also seen during heatingof the reference glass at 100 °C. A further reaction was seen when measured aftera 550 °C heating. A modified APPT treatment with deionized water as precursor wasused. The results show that the APPT with water does not lower the level of non bridgingoxygen and the bonding was further improved.This is an article is based on parts of research performed within the project Joining of Float glass. The project was fundedby FFI, a partnership programme run jointly by the Swedish state and the Swedish automotive industry. The FFI fundsresearch, innovation and development with an emphasis on climate, the environment and safety.
Qiuheng Zhang - One of the best experts on this subject based on the ideXlab platform.
-
understanding the correlation between dsa complement activation and antibody mediated rejection in heart transplant recipients
Transplantation, 2018Co-Authors: Qiuheng Zhang, Michelle J Hickey, Diana Drogaliskim, Ying Zheng, David W Gjertson, Martin Cadeiras, T Khuu, A Baas, E C Depasquale, Nancy J HalnonAbstract:BACKGROUND Donor-specific HLA antibodies (DSA) are associated with increased rates of rejection and of graft failure in cardiac transplantation. The goal of this study was to determine the association of preformed and posttransplant development of newly detected DSA (ndDSA) with antibody-mediated rejection (AMR) and characterize the clinical relevance of complement-activating DSA in heart allograft recipients. METHODS The study included 128 adult and 48 pediatric heart transplant patients transplanted between 2010 and 2013. Routine posttransplant HLA antibody Testing was performed by IgG single-antigen Bead Test. The C3d single-antigen Bead assay was used to identify complement-activating antibodies. Rejection was diagnosed using International Society for Heart and Lung Transplantation criteria. RESULTS In this study, 22 patients were transplanted with preexisting DSA, and 43 patients developed ndDSA posttransplant. Pretransplant (P < 0.05) and posttransplant (P < 0.001) ndDSA were associated with higher incidence of AMR. Patients with C3d + DSA had significantly higher incidence of AMR compared with patients with no DSA (P < 0.001) or patients with C3d-DSA (P = 0.02). Nine (36%) of 25 patients with AMR developed transplant coronary artery disease compared with 17 (15.9%) of 107 patients without AMR (P < 0.05). Among the 47 patients who received ventricular assistant device (VAD), 7 of 9 VAD+ patients with preformed DSA experienced AMR compared with 7 of 38 VAD+ patients without preformed DSA, indicating presensitization to donor HLA significantly increased the risk of AMR (P < 0.01). CONCLUSIONS Preformed and posttransplant ndDSA were associated with AMR. C3d + DSA correlates with complement deposition on the graft and higher risk of AMR which may permit the application of personalized immunotherapy targeting the complement pathway.
Ying Zheng - One of the best experts on this subject based on the ideXlab platform.
-
understanding the correlation between dsa complement activation and antibody mediated rejection in heart transplant recipients
Transplantation, 2018Co-Authors: Qiuheng Zhang, Michelle J Hickey, Diana Drogaliskim, Ying Zheng, David W Gjertson, Martin Cadeiras, T Khuu, A Baas, E C Depasquale, Nancy J HalnonAbstract:BACKGROUND Donor-specific HLA antibodies (DSA) are associated with increased rates of rejection and of graft failure in cardiac transplantation. The goal of this study was to determine the association of preformed and posttransplant development of newly detected DSA (ndDSA) with antibody-mediated rejection (AMR) and characterize the clinical relevance of complement-activating DSA in heart allograft recipients. METHODS The study included 128 adult and 48 pediatric heart transplant patients transplanted between 2010 and 2013. Routine posttransplant HLA antibody Testing was performed by IgG single-antigen Bead Test. The C3d single-antigen Bead assay was used to identify complement-activating antibodies. Rejection was diagnosed using International Society for Heart and Lung Transplantation criteria. RESULTS In this study, 22 patients were transplanted with preexisting DSA, and 43 patients developed ndDSA posttransplant. Pretransplant (P < 0.05) and posttransplant (P < 0.001) ndDSA were associated with higher incidence of AMR. Patients with C3d + DSA had significantly higher incidence of AMR compared with patients with no DSA (P < 0.001) or patients with C3d-DSA (P = 0.02). Nine (36%) of 25 patients with AMR developed transplant coronary artery disease compared with 17 (15.9%) of 107 patients without AMR (P < 0.05). Among the 47 patients who received ventricular assistant device (VAD), 7 of 9 VAD+ patients with preformed DSA experienced AMR compared with 7 of 38 VAD+ patients without preformed DSA, indicating presensitization to donor HLA significantly increased the risk of AMR (P < 0.01). CONCLUSIONS Preformed and posttransplant ndDSA were associated with AMR. C3d + DSA correlates with complement deposition on the graft and higher risk of AMR which may permit the application of personalized immunotherapy targeting the complement pathway.